Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

(2011) Anne-Joy M. de Graan et al.   JOURNAL OF CLINICAL ONCOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

(2011) Joachim Lupberger et al.   NATURE MEDICINE

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

(2010) CF Samer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor

(2010) A. Ghosal et al.   DRUG METABOLISM AND DISPOSITION

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

(2009) Shu-Feng Zhou   CLINICAL PHARMACOKINETICS

New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

(2009) Bo Wang et al.   DRUG METABOLISM REVIEWS

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

(2008) M C Rebsamen et al.   PHARMACOGENOMICS JOURNAL

Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: Application to the assessment of CYP2D6 activity in fibromyalgia patients

(2007) Y. Daali et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES